CVRx to Report First Quarter 2024 Financial and Operating Results and Host Conference Call on April 30th, 2024
April 16, 2024 16:30 ET
|
CVRx, Inc.
MINNEAPOLIS, April 16, 2024 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing Barostim™, an...
CVRx announces availability of additional data supporting long-term benefits of Barostim
April 15, 2024 07:30 ET
|
CVRx, Inc.
BeAT-HF trial data published in the European Journal of Heart Failure and new abstracts presented at THT conference MINNEAPOLIS, Minn., April 15, 2024 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX)...
CVRx Announces Appointment of Kevin Hykes as President and Chief Executive Officer
January 31, 2024 08:00 ET
|
CVRx, Inc.
Appointment effective February 12 following Nadim Yared’s retirement Hykes currently serves as Augmedics’ President and CEO, and has served on CVRx’s Board of Directors since 2022 MINNEAPOLIS, Jan. ...
CVRx Reports Fourth Quarter and Full Year 2023 Financial and Operating Results
January 25, 2024 16:05 ET
|
CVRx, Inc.
MINNEAPOLIS, Jan. 25, 2024 (GLOBE NEWSWIRE) -- CVRx, Inc. (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation...
CVRx to Report Fourth Quarter 2023 Financial and Operating Results and Host Conference Call on January 25th, 2024
January 11, 2024 16:30 ET
|
CVRx, Inc.
MINNEAPOLIS, Jan. 11, 2024 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing Barostim™, an...
CVRx Reports Preliminary Fourth Quarter and Fiscal Year 2023 Financial Results and Announces Nadim Yared Retirement Plans
January 08, 2024 08:30 ET
|
CVRx, Inc.
Fourth quarter revenue expected to be $11.2 million to $11.3 million, representing growth of 56% to 58%Full year revenue expected to be $39.2 million to $39.3 million, representing growth of 74% to...
CVRx to Present at the 42nd Annual J.P. Morgan Healthcare Conference
December 27, 2023 16:30 ET
|
CVRx, Inc.
MINNEAPOLIS, Dec. 27, 2023 (GLOBE NEWSWIRE) -- CVRx, Inc. (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation...
CVRx receives FDA approval for expanded labeling of Barostim
December 26, 2023 08:05 ET
|
CVRx, Inc.
MINNEAPOLIS, Dec. 26, 2023 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company, announced today that the U.S. Food and Drug Administration (FDA) has...
CVRx to Present at the 35th Annual Piper Sandler Healthcare Conference
November 15, 2023 16:21 ET
|
CVRx, Inc.
MINNEAPOLIS, Nov. 15, 2023 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative...
CMS Increases Outpatient Payment for Barostim Procedure
November 03, 2023 08:00 ET
|
CVRx, Inc.
MINNEAPOLIS, Nov. 03, 2023 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company, announced today that Centers for Medicare and Medicaid Services (CMS)...